Adia Nutrition Launches Second National Television Campaign Showcasing U.S.-Based Regenerative Stem Cell Therapies

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) has launched its second national television campaign highlighting Adia Med's regenerative stem cell treatments at its Winter Park, Florida clinic. The campaign emphasizes U.S.-based therapies for conditions including sports injuries, orthopedic care, chronic pain, and wound repair.

The company is targeting the $25 billion wound care market and aims to make regenerative therapies more accessible domestically. Adia Med is currently in-network with UnitedHealthcare and Aetna, with pending TRICARE approval. The initiative is supported by favorable legislation like Florida's SB1768, which recognizes stem cell therapy benefits.

Positive

• Entry into the large $25 billion wound care market
• In-network status with major insurers UnitedHealthcare and Aetna
• Favorable regulatory environment with Florida's SB1768 legislation
• Strategic expansion through licensing opportunities and partnerships

Negative

• Operating in a highly competitive regenerative medicine market
• Pending TRICARE approval indicates incomplete insurance coverage

News Market Reaction – ADIA

-1.82%

1 alert

-1.82% News Effect

On the day this news was published, ADIA declined 1.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Winter Park, Florida--(Newsfile Corp. - August 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized healthcare, today announced the launch of its second nationwide television campaign. The commercial highlights Adia Med, the company's clinical division, and its advanced regenerative stem cell treatments now available at the flagship Winter Park, Florida clinic. These therapies are designed for a wide range of conditions including sports injuries, orthopedic care, chronic pain, and advanced wound repair.

Adia Nutrition launches second nationwide commercial

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/263215_adia.jpg

The TV campaign comes on the heels of Adia Med's entry into the $25 billion wound care market and showcases the company's broader mission to make world-class regenerative therapies accessible in the United States. For years, many Americans traveled abroad to receive high-quality stem cell treatments, believing they were unavailable domestically. Adia Med is proving that is no longer the case - delivering safe, effective, and U.S.-based regenerative therapies supported by advanced protocols and comprehensive patient care.

Click Here to Watch Commercial

"This nationwide commercial is about showing patients they don't need to leave the country to get access to cutting-edge regenerative medicine," said Larry Powalisz, CEO of Adia Nutrition Inc. "It's available right here at home, and we're doing it in a way that meets the highest U.S. medical standards. For patients, it means better access and peace of mind. For investors, it represents a growing market opportunity that we are well-positioned to lead."

Momentum is also being supported by favorable policy trends, including Florida's passage of SB1768, which formally recognizes the regenerative benefits of stem cell therapy. This legislation underscores the growing legitimacy of regenerative medicine in the U.S. and strengthens Adia Med's position as a pioneer in the field.

The new commercial, airing on major TV networks, presents Adia Med as a destination clinic for regenerative healthcare. Treatments focus on accelerating recovery, improving mobility, and enhancing quality of life, while avoiding the need for costly and burdensome medical travel abroad.

Adia Med is currently an in-network provider with UnitedHealthcare and Aetna, with an active filing underway with TRICARE to broaden access further. The campaign is both a brand-building milestone and a patient acquisition engine, reinforcing Adia's mission to deliver regenerative therapies that are accessible, affordable, and nationally recognized.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263215

FAQ

What treatments does Adia Med (OTCQB: ADIA) offer in its stem cell therapy program?

Adia Med offers regenerative stem cell treatments for sports injuries, orthopedic care, chronic pain, and advanced wound repair at their Winter Park, Florida clinic.

Which insurance providers cover Adia Med's stem cell treatments?

Adia Med is currently an in-network provider with UnitedHealthcare and Aetna, and has a pending application with TRICARE.

What is the size of the wound care market that Adia Nutrition is targeting?

Adia Nutrition is entering the $25 billion wound care market with its regenerative stem cell treatments.

How does Florida's SB1768 legislation affect Adia Med's business?

Florida's SB1768 formally recognizes the regenerative benefits of stem cell therapy, strengthening Adia Med's position as a pioneer in the field and providing regulatory support.

Where is Adia Med's flagship stem cell treatment clinic located?

Adia Med's flagship clinic is located in Winter Park, Florida, offering U.S.-based regenerative therapies.